Core Laboratories N.V.
CLB · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $812 | $824 | $939 | $1,026 |
| - Cash | $19 | $15 | $15 | $18 |
| + Debt | $180 | $215 | $222 | $250 |
| Enterprise Value | $973 | $1,025 | $1,146 | $1,259 |
| Revenue | $524 | $510 | $490 | $470 |
| % Growth | 2.8% | 4.1% | 4.1% | – |
| Gross Profit | $88 | $94 | $79 | $84 |
| % Margin | 16.9% | 18.4% | 16.1% | 17.8% |
| EBITDA | $73 | $70 | $59 | $64 |
| % Margin | 14% | 13.8% | 12% | 13.6% |
| Net Income | $31 | $37 | $19 | $20 |
| % Margin | 6% | 7.2% | 4% | 4.2% |
| EPS Diluted | 0.66 | 0.77 | 0.42 | 0.42 |
| % Growth | -14.3% | 83.3% | 0% | – |
| Operating Cash Flow | $56 | $25 | $25 | $37 |
| Capital Expenditures | -$13 | -$11 | -$10 | -$14 |
| Free Cash Flow | $43 | $14 | $15 | $23 |